FDA Proposes Allowing Waiver or Alteration of Informed Consent for Minimal Risk Research

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

FDA Proposes Allowing Waiver or Alteration of Informed Consent for Minimal Risk Research

J.W. Schomisch

November 13, 2018 at 01:26 PM EST

The FDA proposed allowing Institutional Review Board waiver or alteration of informed consent for minimal risk clinical investigations Nov. 13. “This change would facilitate the conduct of certain minimal risk clinical investigations that may be important to addressing significant public health needs without compromising the rights, safety, or welfare of human subjects,” FDA ... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

FDA Proposes Allowing Waiver or Alteration of Informed Consent for Minimal Risk Research

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT